Amylyx Pharmaceuticals (AMLX) Analyst & Key Data

Analyst Consensus

Buy18 analysts

Buy

Updated Sep 12, 2026

Total Analysts18

Buy

10

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$31.62

Median Target+13.31%

$35.83

Potential upside vs current price

DCF Value-92.73%

$2.30

Potential downside vs current price

Current Stock Price

$31.62

Median Target+13.31%

$35.83

Potential upside vs current price

DCF Value-92.73%

$2.30

Potential downside vs current price

Analyst Consensus

Buy18 analysts

Buy

Updated Sep 12, 2026

Total Analysts18

Buy

10

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$31.62

Median Target+13.31%

$35.83

Potential upside vs current price

DCF Value-92.73%

$2.30

Potential downside vs current price

Current Stock Price

$31.62

Median Target+13.31%

$35.83

Potential upside vs current price

DCF Value-92.73%

$2.30

Potential downside vs current price

Amylyx Pharmaceuticals, Inc.